Invex Therapeutics Ltd (ASX:IXC)
Australia flag Australia · Delayed Price · Currency is AUD
0.110
0.00 (0.00%)
Mar 9, 2026, 3:03 PM AEST

Invex Therapeutics Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2020 - 2019
Net Income
-0.84-0.48-1.64-7.75-3.95-2.28
Upgrade
Stock-Based Compensation
0.020.020.140.480.350.56
Upgrade
Other Operating Activities
-0.160.02-0.040.0200
Upgrade
Change in Accounts Receivable
-0-00.24-0.19-0.120.1
Upgrade
Change in Accounts Payable
-0.21-0.21-1.140.570.35-0.05
Upgrade
Operating Cash Flow
-1.19-0.65-2.44-6.87-3.38-1.68
Upgrade
Issuance of Common Stock
-----8.65
Upgrade
Repurchase of Common Stock
---14---
Upgrade
Other Financing Activities
------0.55
Upgrade
Financing Cash Flow
---14--8.09
Upgrade
Foreign Exchange Rate Adjustments
-0.020----
Upgrade
Net Cash Flow
-1.21-0.65-16.45-6.87-3.386.42
Upgrade
Cash Income Tax Paid
--0.23-1.21-0.46--
Upgrade
Levered Free Cash Flow
-1.05-0.64-2.1-4.48-1.95-2.23
Upgrade
Unlevered Free Cash Flow
-1.05-0.64-2.1-4.48-1.95-2.23
Upgrade
Change in Working Capital
-0.21-0.21-0.90.380.220.04
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.